Netherlands· NL-e4f159ea62b8
Livmarli 19 mg/ml, drank
A maralixibat chloride product containing maralixibatchloride, registered in Netherlands by Mirum Pharmaceuticals International B.V.. The same ATC class is registered in 11 of our 19 countries.
Checked against CBG-MEB (Netherlands) on
Informational only — not a medical device.
Where it is registered
Maralixibat chloride is registered in 11 of 19 countries.
Countries holding a registration under ATC A05AX04 (maralixibat chloride), each read from that country’s own register.
- This record: Netherlands, from CBG-MEB (Netherlands)
- 6 of them publish a price we can compare per daily dose
Maralixibat chloride · ATC A05AX04
11 / 19 countries
- Belgiumprice
- Canada
- Czechiaprice
- Denmark
- Finlandprice
- Icelandprice
- Ireland
- Japan
- Netherlands
- Polandprice
- Switzerlandprice
The record
At a glance
CBG-MEB (Netherlands)- Active substance
- MARALIXIBATCHLORIDE
- Manufacturer
- Mirum Pharmaceuticals International B.V.
- Country
- Netherlands (NL)
- ATC code
- A05AX04
- ATC class
- Maralixibat chloride
- Defined daily dose
- 28.5 mg, O
- Reimbursed
- Not published by this register
- Source register
- CBG-MEB (Netherlands)
- Last checked
- September 29, 2026
Packs & prices · 1
- cbg_meb_idEU/1/22/1704
Regulatory notes
No shortage, Orange Book or US label notes for this record.
Same class
Other records under A05AX04
Maralixibat chloride, as other registers publish it.
- FinlandLivmarliMirum Pharmaceuticals International B.V.
- PolandLivmarliMirum Pharmaceuticals International B.V.
- FinlandLivmarliMirum Pharmaceuticals International B.V.
- DenmarkLivmarliMirum Pharmaceuticals International B.V.
- FinlandLivmarliMirum Pharmaceuticals International B.V.
- FinlandLivmarliMirum Pharmaceuticals International B.V.
- DenmarkLivmarliMirum Pharmaceuticals International B.V.
- DenmarkLivmarliMirum Pharmaceuticals International B.V.
Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of CBG-MEB (Netherlands). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.
For developers
The same record over the API, and the raw payload
GET /v1/drugs/fb47e7dc-4092-446c-a934-4a698d70099a GET /v1/drugs/fb47e7dc-4092-446c-a934-4a698d70099a?format=fhir
Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.
{
"form": "Drank",
"route": "Oraal gebruik",
"soort": null,
"source": "cbg_meb",
"smpc_url": "https://www.ema.europa.eu/en/documents/product-information/livmarli-epar-product-information_nl.pdf",
"strength": null,
"atc_label": "Maralixibat chloride",
"detail_url": "https://www.geneesmiddeleninformatiebank.nl/nl/cp134335",
"excipients": [
"DINATRIUMEDETAAT 2-WATER",
"DRUIVENSMAAKSTOF",
"PROPYLEENGLYCOL (E 1520)",
"PROPYLEENGLYCOL (E 1520)",
"SUCRALOSE (E 955)",
"WATER, GEZUIVERD"
],
"substances": [
"MARALIXIBATCHLORIDE"
],
"leaflet_url": null,
"authorised_at": "2022/12/09",
"procedure_number": "EMEA/H/C/005857",
"dispensing_status": "Uitsluitend recept",
"registration_number": "EU/1/22/1704",
"additional_monitoring": "Y"
}See everything about maralixibat chloride.
This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.